[1] GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015[J]. Lancet, 2016, 388(10053):1459-1544.
[2] Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report[J]. JAMA, 2003, 289(19):2560-2572.
[3] Dauphinot V, Kossovsky MP, Gueyffier F, et al. Impaired baroreflex sensitivity and the risks of new-onset ambulatory hypertension, in an elderly population-based study[J]. Int J Cardiol, 2013, 168(4):4010-4014.
[4] Grassi G, Seravalle G, Brambilla G, et al. Marked sympathetic activation and baroreflex dysfunction in true resistant hypertension[J]. Int J Cardiol, 2014, 177(3):1020-1025.
[5] Pinna GD, Maestri R, Capomolla S, et al. Applicability and clinical relevance of the transfer function method in the assessment of baroreflex sensitivity in heart failure patients[J]. J Am Coll Cardiol, 2005, 46(7):1314-1321.
[6] 苏定冯.动脉压力感受性反射与心血管疾病[M].//苏定冯,缪朝玉,主编.心血管药理学.2版,北京:科学出版社,2010:101-109.
[7] Heusser K, Tank J, Engeli S, et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients[J]. Hypertension, 2010, 55(3):619-626.
[8] Shen MJ, Zipes DP. Interventional and device-based autonomic modulation in heart failure[J]. Heart Fail Clin, 2015, 11(2):337-348.
[9] Acelajado MC, Calhoun DA. Resistant hypertension, secondary hypertension, and hypertensive crises: diagnostic evaluation and treatment[J]. Cardiol Clin, 2010, 28(4):639-654.
[10] Hoppe UC, Brandt MC, Wachter R, et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial[J]. J Am Soc Hypertens, 2012, 6(4):270-276.
[11] Mozaffarian D, Benjamin EJ, Go AS,et al. Heart disease and stroke statistics-2016 update: A report from the American Heart Association[J]. Circulation, 2016, 133(4):e38-360.
[12] Forfar JC. Neuroendocrine activation in congestive heart failure[J]. Am J Cardiol, 1991, 67(12):3C-5C.
[13] Keivanidou A, Fotiou D, Arnaoutoglou C, et al. Evaluation of autonomic imbalance in patients with heart failure: a preliminary study of pupillomotor function[J]. Cardiol J, 2010, 17(1):65-72.
[14] Abraham WT, Zile MR, Weaver FA, et al. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction[J]. JACC Heart Fail, 2015, 3(6):487-496.
[15] Richards AM, Troughton R, Lainchbury J, et al. Guiding and monitoring of heart failure therapy with NT-ProBNP: concepts and clinical studies[J]. J Card Fail, 2005, 11(5 Suppl):S34-37.
[16] Collins AJ, Foley RN, Gilbertson DT, et al. The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis[J]. Clin J Am Soc Nephrol, 2009, 4 (Suppl 1):S5-11.
[17] Converse RL, Jr., Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure[J]. N Engl J Med, 1992, 327(27):1912-1918.
[18] Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease[J]. Circulation, 2002, 105(11):1354-1359.
[19] Beige J, Koziolek MJ, Hennig G, et al. Baroreflex activation therapy in patients with end-stage renal failure: proof of concept[J]. J Hypertens, 2015, 33(11):2344-2349.
[20] Wheeler DC, Becker GJ. Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease?[J]. Kidney Int, 2013, 83(3):377-383.
[21] Pollare T, Lithell H, Selinus I, et al. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients[J]. BMJ, 1989, 298(6681):1152-1157.
[22] Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension[J]. N Engl J Med, 1989, 321(13):868-873.
[23] Chazova I, Almazov VA, Shlyakhto E. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin[J]. Diabetes Obes Metab, 2006, 8(4):456-465.
[24] Wallbach M, Lehnig LY, Helms HJ, et al. Long-term effects of baroreflex activation therapy on glucose metabolism[J]. Acta Diabetol, 2015, 52(5):829-835.
[25] Palatini P. Sympathetic overactivity in hypertension: a risk factor for cardiovascular disease[J]. Curr Hypertens Rep, 2001, 3 (Supp11):S3-S9.
[26] Lohmeier TE, Iliescu R, Dwyer TM, et al. Sustained suppression of sympathetic activity and arterial pressure during chronic activation of the carotid baroreflex[J]. Am J Physiol Heart Circ Physiol, 2010, 299(2):H402-H409.
[27] Lohmeier TE, Iliescu R. Lowering of blood pressure by chronic suppression of central sympathetic outflow: insight from prolonged baroreflex activation[J]. J Appl Physiol, 2012, 113(10):1652-1658.
[28] Alnima T, de Leeuw PW, Tan FE, et al, Rheos Pivotal Trial I. Renal responses to long-term carotid baroreflex activation therapy in patients with drug-resistant hypertension[J]. Hypertension, 2013, 61(6):1334-1339.
[29] Lohmeier TE, Iliescu R, Liu B, et al. Systemic and renal-specific sympathoinhibition in obesity hypertension[J]. Hypertension, 2012, 59(2):331-338.
[30] Bakris GL, Nadim MK, Haller H, et al. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial[J]. J Am Soc Hypertens, 2012, 6(2):152-158.
[31] Bisognano JD, Kaufman CL, Bach DS, et al. Improved cardiac structure and function with chronic treatment using an implantable device in resistant hypertension: results from European and United States trials of the Rheos system[J]. J Am Coll Cardiol, 2011, 57(17):1787-1788.
[32] La Rovere MT, Christensen JH. The autonomic nervous system and cardiovascular disease: role of n-3 PUFAs[J]. Vascul Pharmacol, 2015, 71:1-10.
[33] Gronda E, Seravalle G, Trevano FQ, et al. Long-term chronic baroreflex activation: persistent efficacy in patients with heart failure and reduced ejection fraction[J]. J Hypertens, 2015, 33(8):1704-1708.
[34] Scheffers IJ, Kroon AA, de Leeuw PW. Carotid baroreflex activation: past, present, and future[J]. Curr Hypertens Rep, 2010, 12(2):61-66.